BTK Inhibitors for the Treatment of Relapsed CLL

News
Video

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      A panel of 3 experts on CML
      When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
      A panel of 3 experts on CML
      Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
      A panel of 3 experts on CML
      Starting CML Treatment: Collaborative Choices for Better Outcomes
      Related Content
      The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

      Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

      Ashling Wahner
      June 3rd 2025
      Article

      The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Elizabeth Shpall, MD
      May 29th 2019
      Podcast

      Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

      With longer-term follow-up, investigators observed no new safety signals for zanubrutinib in patients with CLL or SLL harboring 17p deletions.

      Zanubrutinib Shows Sustained Efficacy in Chronic Lymphocytic Leukemia

      Ashley Chan
      May 31st 2025
      Article

      With longer-term follow-up, investigators observed no new safety signals for zanubrutinib in patients with CLL or SLL harboring 17p deletions.

      Immunotherapy Approaches in AML

      Immunotherapy Approaches in AML

      Naval Daver, MD
      January 17th 2019
      Podcast

      Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

      3 Things You Should Know About Advances in CLL Management

      3 Things You Should Know About Advances in CLL Management

      ONCOLOGY Staff
      May 20th 2025
      Article

      Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.

      Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

      Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

      Russ Conroy
      May 9th 2025
      Article

      Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.